spacer
home > ebr > autumn 2017 > risk ratio
PUBLICATIONS
European Biopharmaceutical Review

Risk Ratio

On 30 August 2017, the US FDA formally approved the application for Kymriah, a cancer immunotherapy utilising modified human T-cells that express chimeric antigen receptors (CAR-T). This momentous event follows a decade of intense work to commercialise a therapy that was first demonstrated in 2011 in a handful of terminal paediatric leukaemia patients. At this moment, many CAR variants are in development, alongside a biotechnology business frenzy.

Pre-genomic immunotherapy consisted of human immunoglobulin injections to boost immunity during disease outbreaks. Clearly, this was a blunt instrument. Half a century later, a group at the University of Pennsylvania described remission in paediatric patients with refractory chronic lymphocytic leukaemia using genetically modified immune cells. Furthermore, at the beginning of September 2017, the first ever approval of CAR-T therapy was granted by the FDA for cases of acute lymphoblastic leukaemia in children and young adults. This inverts the usual regulatory paradigm by approving paediatric indications first.

In their Harvard Business Review paper ‘How to Spot a Technological Winner’, Graham and White discuss the factors that influence the success of a transformative innovation. The present intensity of the commercial race in cancer immunotherapy and gene-editing reflects a belief within the biopharmaceutical community that the trade-off of business drivers and technical hurdles is favourable. In just a few years, the number of groups working in this field has expanded from just a handful to over 200.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board and an industry consultant with experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Laboratory Gains ISO 17025 Accreditation for Transit Simulation

Medical Engineering Technologies’ packaging laboratory now has ISTA 2A and ASTM D4169 transit testing added to its accreditation.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement